LAKEFRONT BIOTHERAPEUTIC-ADR
LKFTNASDAQ🏆 #1579 by market capEarnings Nov 12US Equity
$28.73▲ $1.94 (+6.76%)
Live1h—
24h▲ 6.8%
7d—
14d—
30d—
1y—
🏦Market Cap
$1.89B
Small Cap
📈Revenue Growth (YoY)
+81.3%
High Growth
📊Gross Margin
99.0%
High
💵FCF Margin
—
⚖️P/S Ratio
1.6x
Cheap
Otter Score
60
Fair
No chart data available for LKFT.
Trading Snapshot
- Day Range
- $28.39 – $29.08
- 52-Week Range
- —
- Volume
- $2.32B
- Avg Volume
- $2.66B
- Shares Outstanding
- 65.9M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.11B
- Last Q Revenue
- $6M
- P/E Ratio
- 3.1
- P/S Ratio
- 1.6x
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own LKFT
- ✓High-growth profile — revenue up +0.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$1.11B▲ +4.0% YoY
Gross Margin (TTM)
35.8%▼ −0.3% YoY
Operating Income (TTM)
$354M▲ +4.0% YoY
Free Cash Flow (TTM)
$329M▲ +4.0% YoY
About LAKEFRONT BIOTHERAPEUTIC-ADR
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
60/100
Analyst Ratings
ⓘConsensus
Hold
18 analysts
Strong Buy2
Buy1
Hold6
Sell6
Strong Sell3
Ratings as of Aug 2026